JULPHAR Stock Overview
Manufactures and sells medicines, drugs, and other pharmaceutical, medical, cosmetic compounds in the United Arab Emirates, other GCC countries, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Gulf Pharmaceutical Industries P.S.C. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.إ1.21 |
| 52 Week High | د.إ1.78 |
| 52 Week Low | د.إ0.75 |
| Beta | -0.038 |
| 1 Month Change | -14.18% |
| 3 Month Change | 30.11% |
| 1 Year Change | 55.13% |
| 3 Year Change | -33.52% |
| 5 Year Change | -19.49% |
| Change since IPO | -17.80% |
Recent News & Updates
Recent updates
Improved Revenues Required Before Gulf Pharmaceutical Industries P.S.C. (ADX:JULPHAR) Stock's 26% Jump Looks Justified
Oct 16
Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
Jan 15Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Price Is Right But Growth Is Lacking
Nov 04Gulf Pharmaceutical Industries P.S.C's (ADX:JULPHAR) Solid Profits Have Weak Fundamentals
Mar 26Gulf Pharmaceutical Industries P.S.C's(ADX:JULPHAR) Share Price Is Down 59% Over The Past Five Years.
Feb 08Here's What Gulf Pharmaceutical Industries P.S.C.'s (ADX:JULPHAR) Shareholder Ownership Structure Looks Like
Dec 14Shareholder Returns
| JULPHAR | AE Pharmaceuticals | AE Market | |
|---|---|---|---|
| 7D | -6.9% | -1.7% | 1.3% |
| 1Y | 55.1% | 8.3% | 1.8% |
Return vs Industry: JULPHAR exceeded the AE Pharmaceuticals industry which returned 8.3% over the past year.
Return vs Market: JULPHAR exceeded the AE Market which returned 1.8% over the past year.
Price Volatility
| JULPHAR volatility | |
|---|---|
| JULPHAR Average Weekly Movement | 12.6% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in AE Market | 8.8% |
| 10% least volatile stocks in AE Market | 2.1% |
Stable Share Price: JULPHAR's share price has been volatile over the past 3 months compared to the AE market.
Volatility Over Time: JULPHAR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of AE stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | n/a | Basel Nimer Ziyadeh | www.julphar.net |
Gulf Pharmaceutical Industries P.S.C., together with its subsidiaries, manufactures and sells medicines, drugs, and other pharmaceutical, medical, cosmetic compounds in the United Arab Emirates, other GCC countries, and internationally. It operates through Manufacturing, Plant, Investment, and Others segment. The company provides generic medicines for pain management, GIT and endocrine, antiviral, respiratory, anti-infectives, cardio care, wound care, dermatology, CNS and psychiatry, biotechnology, gynecology women care, anemia, antibiotics, inflammation, and erectile dysfunction, as well as consumer care products, mouth wash, and vitamins and supplements.
Gulf Pharmaceutical Industries P.S.C. Fundamentals Summary
| JULPHAR fundamental statistics | |
|---|---|
| Market cap | د.إ1.40b |
| Earnings (TTM) | -د.إ25.10m |
| Revenue (TTM) | د.إ1.71b |
0.8x
P/S Ratio-55.7x
P/E RatioIs JULPHAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JULPHAR income statement (TTM) | |
|---|---|
| Revenue | د.إ1.71b |
| Cost of Revenue | د.إ1.08b |
| Gross Profit | د.إ629.40m |
| Other Expenses | د.إ654.50m |
| Earnings | -د.إ25.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.022 |
| Gross Margin | 36.75% |
| Net Profit Margin | -1.47% |
| Debt/Equity Ratio | 121.2% |
How did JULPHAR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 21:05 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gulf Pharmaceutical Industries P.S.C. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null RESEARCH DEPARTMENT | Prime Research |